Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 7/2017

01-07-2017 | Head and Neck Cancer (L Licitra, Section Editor)

Overview of the 8th Edition TNM Classification for Head and Neck Cancer

Authors: Shao Hui Huang, MD, MSc, MRT(T), Brian O’Sullivan, MD

Published in: Current Treatment Options in Oncology | Issue 7/2017

Login to get access

Opinion Statement

The main purpose of the TNM system is to provide an anatomic-based classification to adequately depict cancer prognosis. Accurate cancer staging is important for treatment selection and outcome prediction, research design, and cancer control activities. To maintain clinical relevance, periodical updates to TNM are necessary. The recently published 8th edition TNM classification institutes the following changes to the staging of head and neck (excluding thyroid cancer): new stage classifications [HPV-related oropharyngeal cancer (HPV+ OPC) and soft tissue sarcoma of the head and neck (HN-STS)] and modification of T and N categories [T and N categories for nasopharyngeal cancer (NPC), T categories for oral cavity squamous cell carcinomas (OSCC), N categories for non-viral related head and neck cancer and unknown primary (CUP), and T categories for head and neck cutaneous carcinoma]. These changes reflect better understanding tumor biology and clinical behavior (e.g., HPV+ OPC and HN-STS), improved outcomes associated with technical advances in diagnosis and treatment (e.g., NPC), evolving knowledge about additional prognostic factors and risk stratification from research and observation (e.g., inclusion of depth of invasion variable for OSCC, inclusion of extranodal extension variable for all non-viral head and neck cancer, and reintroduction of size criteria for non-Merkel cell cutaneous carcinoma of the head and neck). This review summarizes the changes and potential advantages and limitations/caveats associated with them. Further evidence is needed to evaluate whether these changes would result in improvement in TNM stage performance to better serve the needs for clinical care, research, and cancer control.
Literature
1.
2.
American Joint Committee for Cancer Staging and End-Results Reporting (AJC). Manual for staging of cancer 1977. American Joint Committee on Cancer 1977.
3.
Sobin LH, Brierley J, Gospodarowicz M, et al. Principles of cancer staging. In: O'Sullivan B, Brierley J, D'Cruz A, et al., editors. UICC manual of clinical oncology. 9th ed. Chichester: Wiley; 2015. p. 34–9.CrossRef
4.
Gospodarowicz MK, Miller D, Groome PA, et al. The process for continuous improvement of the TNM classification. Cancer. 2004;100:1–5.CrossRefPubMed
5.
Brierley J, Gospodarowicz M, Wittekind C. UICC TNM classification of malignant tumours. Eighth ed. Chichester: Wiley; 2017.
6.
Amin M, Edge S, Greene F, et al. AJCC cancer staging manual. Eighth ed. New York: Springer; 2017.CrossRef
7.
O'Sullivan B. Head and neck tumours. In: Brierley J, Gospodarowicz M, Ch W, et al., editors. UICC TNM classification of Malignant Tumours. Eighth ed. Chichester: Wiley; 2017. p. 17–54.
8.
O'Sullivan B, Lydiatt W, Haughey BH, et al. HPV-mediated (p16+) oropharyngeal cancer. In: Amin M, Edge S, Greene F, et al., editors. AJCC cancer staging manual. Eighth ed. New York: Springer; 2017. p. 113–21.CrossRef
9.
O'Sullivan B. Tumours of bone and soft tissues. In: Brierley J, Gospodarowicz M, Ch W, et al., editors. UICC TNM classification of malignant tumours. Eighth ed. Chichester: Wiley; 2017. p. 119–30.
10.
O'Sullivan B, Maki RG, Agulnik M, et al. Soft tissue sarcoma of the head and neck. In: Amin M, Edge S, Greene F, et al., editors. AJCC cancer staging manual. Eighth ed. New York: Springer; 2017. p. 113–21.CrossRef
11.
Patel S, Lydiatt W, Ridge J, et al. Cervical lymph nodes and unknown primary tumors of the head and neck. In: Amin M, Edge S, Greene F, et al., editors. AJCC cancer staging manual. Eighth ed. Swizerland: Springer Nature; 2017. p. 67–78.CrossRef
12.
Lee A, Lydiatt W, Colevas AD, et al. Nasopharynx. In: Amin M, Edge S, Greene F, et al., editors. AJCC cancer staging manual. Eighth ed. New York: Springer; 2017. p. 103–11.CrossRef
13.
Ridge JA, Lydiatt W, Patel SG, et al. Lip and oral cavity. In: Amin M, Edge S, Greene F, et al., editors. AJCC cancer staging manual. Eighth ed. New York: Springer; 2017. p. 79–94.CrossRef
14.
Califano JA, Lydiatt W, Nehal KS, et al. Cutaneous squamous cell carcinoma of the head and neck. In: Amin M, Edge S, Greene F, et al., editors. AJCC cancer staging manual. Eighth ed. New York: Springer; 2017. p. 171–81.CrossRef
15.
Lee A, Brierley J, O'Sullivan B. Skin Tumours. In Brierley J, Gospodarowicz M, Ch W et al. (eds): UICC TNM classification of malignant tumours, Eighth Edition. Chichester Wiley 2017; 131–150.
16.
•• O'Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17:440–51. A large multicenter study proposed clinical TNM classification for HPV-related oropharyngeal cancer which was adopted by the 8 th edition TNM
17.
•• Haughey BH, Sinha P, Kallogjeri D, et al. Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral Oncol. 2016;62:11–9. A large multicenter study proposed pathologic TNM classification for HPV-related oropharyngeal cancer which was adopted by the 8th edition TNM
18.
Dahlstrom KR, Calzada G, Hanby JD, et al. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair. Cancer. 2013;119:81–9.CrossRefPubMed
19.
•• Huang SH, Xu W, Waldron J, et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. J Clin Oncol. 2015;33:836–45. A large single institution cohort study proved the hypothesis that new staging classification is needed and feasible. It also provided the methodology for deriving TNM and evaluation criteria of TNM performanceCrossRefPubMed
20.
Straetmans JM, Olthof N, Mooren JJ, et al. Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope. 2009;119:1951–7.CrossRefPubMed
21.
Malm IJ, Fan CJ, Yin LX et al. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. Cancer 2017.
22.
Husain ZA, Chen T, Corso CD et al. A comparison of prognostic ability of staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. JAMA Oncol 2016.
23.
Dahlstrom KR, Garden AS, William WN Jr, et al. Proposed staging system for patients with HPV-related oropharyngeal cancer based on nasopharyngeal cancer N categories. J Clin Oncol. 2016;34:1848–54.CrossRefPubMedPubMedCentral
24.
•• Sinha P, Kallogjeri D, Gay H, et al. High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer. Oral Oncol. 2015;51:514–20. A large surgical series showing the importance of pathologic lymph node number for HPV-related oropharyngeal cancerCrossRefPubMed
25.
Sinha P, Lewis JS Jr, Piccirillo JF, et al. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer. 2012;118:3519–30.CrossRefPubMed
26.
Sinha P, Lewis JS Jr, Kallogjeri D, et al. Soft tissue metastasis in p16-positive oropharynx carcinoma: prevalence and association with distant metastasis. Oral Oncol. 2015;51:778–86.CrossRefPubMed
27.
El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 2012;34:459–61.CrossRefPubMed
28.
Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1319–31.CrossRefPubMed
29.
Thomas J, Primeaux T. Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma? Ann Diagn Pathol. 2012;16:91–9.CrossRefPubMed
30.
Mattavelli D, Miceli R, Radaelli S, et al. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. Ann Oncol. 2013;24:2181–9.CrossRefPubMed
31.
Park JT, Roh JL, Kim SO, et al. Prognostic factors and oncological outcomes of 122 head and neck soft tissue sarcoma patients treated at a single institution. Ann Surg Oncol. 2015;22:248–55.CrossRefPubMed
32.
• Maxwell JH, Ferris RL, Gooding W, et al. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer. 2013;119:3302–8. A single institution study showed differential impact of extranodal extension for cancer of oral cavity and oropharynxCrossRefPubMed
33.
Myers JN, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer. 2001;92:3030–6.CrossRefPubMed
34.
Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843–50.CrossRefPubMed
35.
• Mermod M, Tolstonog G, Simon C, Monnier Y. Extracapsular spread in head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2016;62:60–71. A single institution study showed differential impact of extranodal extension for cancer of oral cavity and oropharynxCrossRefPubMed
36.
Chai RL, Rath TJ, Johnson JT, et al. Accuracy of computed tomography in the prediction of extracapsular spread of lymph node metastases in squamous cell carcinoma of the head and neck. JAMA Otolaryngol Head Neck Surg. 2013;139:1187–94.CrossRefPubMed
37.
Liu JT, Kann BH, De B, et al. Prognostic value of radiographic extracapsular extension in locally advanced head and neck squamous cell cancers. Oral Oncol. 2016;52:52–7.CrossRefPubMed
38.
Gregoire V, Ang K, Budach W, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014;110:172–81.CrossRefPubMed
39.
•• Pan JJ, Ng WT, Zong JF, et al. Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer. 2016;122:546–58. A multicenter study proposed modified TNM classification for nasopharyngeal carcinoma which was adopted by 8th edition TNM
40.
Peng H, Guo R, Chen L, et al. Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy. Sci Rep. 2016;6:22000.CrossRefPubMedPubMedCentral
41.
Zhang L, Tang LQ, Chen QY, et al. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. Oncotarget. 2016;7:6221–30.CrossRefPubMed
42.
Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004;350:2461–70.CrossRefPubMed
43.
Leung SF, Chan AT, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer. 2003;98:288–91.CrossRefPubMed
44.
Sun P, Chen C, Cheng YK, et al. Serologic biomarkers of Epstein-Barr virus correlate with TNM classification according to the seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2014;271:2545–54.CrossRefPubMed
45.
Guo R, Sun Y, Yu XL, et al. Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol. 2012;104:294–9.CrossRefPubMed
46.
Wu Z, Zeng RF, Su Y, et al. Prognostic significance of tumor volume in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy. Head Neck. 2013;35:689–94.CrossRefPubMed
47.
Wu Z, Gu MF, Zeng RF, et al. Correlation between nasopharyngeal carcinoma tumor volume and the 2002 International Union Against Cancer tumor classification system. Radiat Oncol. 2013;8:87.CrossRefPubMedPubMedCentral
48.
Mucke T, Kanatas A, Ritschl LM, et al. Tumor thickness and risk of lymph node metastasis in patients with squamous cell carcinoma of the tongue. Oral Oncol. 2016;53:80–4.CrossRefPubMed
49.
Pinto FR, de Matos LL, Palermo FC, et al. Tumor thickness as an independent risk factor of early recurrence in oral cavity squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2014;271:1747–54.PubMed
50.
Huang SH, Hwang D, Lockwood G, et al. Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of reported studies. Cancer. 2009;115:1489–97.CrossRefPubMed
51.
O'Brien CJ, Lauer CS, Fredricks S, et al. Tumor thickness influences prognosis of T1 and T2 oral cavity cancer—but what thickness? Head Neck. 2003;25:937–45.CrossRefPubMed
52.
•• Ebrahimi A, Gil Z, Amit M, et al. Primary tumor staging for oral cancer and a proposed modification incorporating depth of invasion: an international multicenter retrospective study. JAMA Otolaryngol Head Neck Surg. 2014;140:1138–48. A large multicenter study demonstrated the importance of depth of invasion for oral cavity cancer and proposed the cutoff for T classification, which was adopted by 8th edition TNM
53.
Madana J, Laliberte F, Morand GB, et al. Computerized tomography based tumor-thickness measurement is useful to predict postoperative pathological tumor thickness in oral tongue squamous cell carcinoma. J Otolaryngol Head Neck Surg. 2015;44:49.CrossRefPubMedPubMedCentral
54.
Goel V, Parihar PS, Parihar A, et al. Accuracy of MRI in prediction of tumour thickness and nodal stage in oral tongue and gingivobuccal cancer with clinical correlation and staging. J Clin Diagn Res. 2016;10:TC01–5.PubMedPubMedCentral
55.
Schmults CD, Karia PS, Carter JB, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149:541–7.CrossRefPubMed
56.
Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9:713–20.CrossRefPubMed
57.
Roozeboom MH, Lohman BG, Westers-Attema A, et al. Clinical and histological prognostic factors local recurrence and metastasis of cutaneous squamous cell carcinoma: analysis of a defined population. Acta Derm Venereol. 2013;93:417–21.CrossRefPubMed
58.
Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23:759–65.CrossRefPubMed
59.
Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149:402–10.CrossRefPubMed
Metadata
Title
Overview of the 8th Edition TNM Classification for Head and Neck Cancer
Authors
Shao Hui Huang, MD, MSc, MRT(T)
Brian O’Sullivan, MD
Publication date
01-07-2017
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 7/2017
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-017-0484-y

Other articles of this Issue 7/2017

Current Treatment Options in Oncology 7/2017 Go to the issue

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases

Upper Gastrointestinal Cancers (L Rajdev, Section Editor)

Immunotherapeutic Approaches to Biliary Cancer

Leukemia (PH Wiernik, Section Editor)

Predispositions to Leukemia in Down Syndrome and Other Hereditary Disorders

Head and Neck Cancer (L Licitra, Section Editor)

The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?

Invited Commentary

What Is New in the World Health Organization 2017 Histopathology Classification?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits